Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology Journal Article


Authors: Suzuki, M.; Curran, K. J.; Cheung, N. K. V.
Article Title: Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology
Abstract: Cancer immunotherapy using antigen-specific T cells has broad therapeutic potential. Chimeric antigen receptors and bispecific antibodies can redirect T cells to kill tumors without human leukocyte antigens (HLA) restriction. Key determinants of clinical potential include the choice of target antigen, antibody specificity, antibody affinity, tumor accessibility, T cell persistence, and tumor immune evasion. For pediatric cancers, additional constraints include their propensity for bulky metastatic disease and the concern for late toxicities from treatment. Nonetheless, the recent preclinical and clinical developments of these T cell based therapies are highly encouraging. © 2015 Wiley Periodicals, Inc.
Keywords: t cells; immunotherapy; pediatric oncology; chimeric antigen receptors; bispecific antibodies
Journal Title: Pediatric Blood and Cancer
Volume: 62
Issue: 8
ISSN: 1545-5009
Publisher: Wiley Periodicals, Inc  
Date Published: 2015-08-01
Start Page: 1326
End Page: 1336
Language: English
DOI: 10.1002/pbc.25513
PROVIDER: scopus
PUBMED: 25832831
PMCID: PMC4976492
DOI/URL:
Notes: Export Date: 3 August 2015 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Nai-Kong Cheung
    648 Cheung
  2. Kevin Joseph Curran
    144 Curran
  3. Maya Suzuki
    13 Suzuki